ImmunityBio, Inc.
IBRX
$8.06
-$0.23-2.77%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 50.67M | 44.17M | 38.27M | 31.78M | 26.42M |
| Total Other Revenue | 568.00K | 39.00K | 13.00K | 281.00K | 4.00K |
| Total Revenue | 51.24M | 44.21M | 38.29M | 32.06M | 26.43M |
| Cost of Revenue | 298.00K | 238.00K | 382.00K | 177.00K | 136.00K |
| Gross Profit | 50.94M | 43.97M | 37.90M | 31.88M | 26.29M |
| SG&A Expenses | 51.82M | 45.77M | 35.33M | 37.38M | 42.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 112.94M | 114.00M | 102.97M | 87.69M | 97.71M |
| Operating Income | -61.70M | -69.79M | -64.68M | -55.63M | -71.29M |
| Income Before Tax | -230.39M | -632.79M | -62.09M | -67.31M | -92.31M |
| Income Tax Expenses | -- | 9.00K | -135.00K | -35.00K | 269.00K |
| Earnings from Continuing Operations | -230.39M | -632.80M | -61.96M | -67.27M | -92.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 12.00K | 15.00K | 14.00K | 21.00K | 19.00K |
| Net Income | -230.38M | -632.78M | -61.94M | -67.25M | -92.56M |
| EBIT | -61.70M | -69.79M | -64.68M | -55.63M | -71.29M |
| EBITDA | -57.29M | -65.41M | -60.92M | -51.68M | -67.41M |
| EPS Basic | -0.22 | -0.62 | -0.06 | -0.07 | -0.10 |
| Normalized Basic EPS | -0.14 | -0.38 | -0.04 | -0.04 | -0.06 |
| EPS Diluted | -0.22 | -0.62 | -0.06 | -0.07 | -0.10 |
| Normalized Diluted EPS | -0.14 | -0.38 | -0.04 | -0.04 | -0.06 |
| Average Basic Shares Outstanding | 1.05B | 1.03B | 989.68M | 946.60M | 888.22M |
| Average Diluted Shares Outstanding | 1.05B | 1.03B | 989.68M | 946.60M | 888.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |